Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients

Abstract

This study supports a possible role of everolimus in liver fibrosis modulation after LT in a clinical setting and suggests that tailoring immunosuppression could avoid fibrosis progression in the allograft.